Filing Details

Accession Number:
0001179110-20-009879
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-09-18 16:20:52
Reporting Period:
2020-09-16
Accepted Time:
2020-09-18 16:20:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1012477 Avadel Pharmaceuticals Plc AVDL Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1390798 Anthony Mark Mccamish C/o Avadel Pharmaceuticals Plc
10 Earlsfort Terrace
Dublin 2 L2 D02 T380
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Adss Acquisiton 2020-09-16 118,602 $5.73 118,602 No 4 P Indirect By Matthew 5 LLC
Adss Acquisiton 2020-09-17 52,398 $5.83 171,000 No 4 P Indirect By Matthew 5 LLC
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Matthew 5 LLC
No 4 P Indirect By Matthew 5 LLC
Footnotes
  1. The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.25 to $5.895, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
  3. Shares held by Matthew 5 LLC. The Mark & Barbara McCamish Family Trust is the sole owner of Matthew 5 LLC, and the Reporting Person serves as its manager.
  4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.68 to $5.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.